EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Effect of Pravastatin on Kidney Function in Patients with Dyslipidemia and Type 2 Diabetes Mellitus: A Multicenter Prospective Observational Study

Hae Jin Kim, Kyu Yeon Hur, Yong-Ho Lee, Jin Taek Kim, Yong-Kyu Lee, Ki-Hyun Baek, Euy Jin Choi, Won Min Hwang, Ki Tae Bang, Jung Soo Lim, Yun Jae Chung, Sung Rae Jo und 4 weitere

Advances in Therapy · 2024

DOI: 10.1007/s12325-024-02862-5 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Advances in Therapy, 2024. Verfasst von Hae Jin Kim und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea. Hauptthemen laut MEDLINE: Pravastatin, Diabetes Mellitus, Type 2, Dyslipidemias, Glomerular Filtration Rate. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daiichisankyo, Korea, Seoul National University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Several studies have reported that pravastatin can mitigate the progression of kidney disease, but limited evidence exists regarding its effects on kidney function in Asian patients. This multicenter prospective observational study aimed to assess the effect of pravastatin on kidney function in Korean patients with dyslipidemia and type 2 diabetes mellitus (T2DM) in clinical practice. METHODS: This 48-week prospective multicenter study included 2604 of 2997 eligible patients with dyslipidemia and T2DM who had available estimated glomerular filtration rate (eGFR) measurements. The primary endpoint was eGFR percent change at week 24 from baseline. We also assessed secondary endpoints, which included percent changes in eGFR at weeks 12 and 48 from baseline, as well as changes in eGFR, metabolic profiles (lipid and glycemic levels) at 12, 24, and 48 weeks from baseline, and safety. RESULTS: We noted a significant improvement in eGFR, with mean percent changes of 2.5%, 2.5%, and 3.0% at 12, 24, and 48 weeks, respectively (all adjusted p 5 years, or previous statin therapy. Lipid profiles were improved and remained stable throughout the study, and interestingly, fasting glucose and HbA1c were improved at 24 weeks. CONCLUSION: Our findings suggest that pravastatin may have potential benefits for improving eGFR in Korean patients with dyslipidemia and T2DM. This could make it a preferable treatment option for patients with reduced kidney function. TRIAL REGISTRATION NUMBER: NCT05107063 submitted October 27, 2021.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PravastatinDiabetes Mellitus, Type 2DyslipidemiasGlomerular Filtration RateHydroxymethylglutaryl-CoA Reductase InhibitorsHumansMaleFemaleMiddle AgedProspective StudiesAgedRepublic of KoreaAdultKidney

Stichwörter der Autor:innen

DyslipidemiaKidney functionPravastatinReal-world dataType 2 diabetes mellitus

Substanzen

PravastatinHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Eulji University College of Medicine, Seoul, Korea.
  • Division of Nephrology, Department of Internal Medicine, NHIC Ilsan Hospital, Goyang, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

ORCID-Profile: Sung Hee Choi

Förderung

  • Daiichisankyo, Korea
  • Seoul National University

Zitieren

APA

Kim, H. J., Hur, K. Y., Lee, Y. H., Kim, J. T., Lee, Y. K., Baek, K. H., Choi, E. J., Hwang, W. M., Bang, K. T., Lim, J. S., Chung, Y. J., Jo, S. R., Oh, J. S., Lee, S. H., Ko, S. H., & Choi, S. H. (2024). Effect of Pravastatin on Kidney Function in Patients with Dyslipidemia and Type 2 Diabetes Mellitus: A Multicenter Prospective Observational Study. Advances in Therapy. https://doi.org/10.1007/s12325-024-02862-5

Vancouver

Kim HJ, Hur KY, Lee YH, Kim JT, Lee YK, Baek KH, et al. Effect of Pravastatin on Kidney Function in Patients with Dyslipidemia and Type 2 Diabetes Mellitus: A Multicenter Prospective Observational Study. Advances in Therapy. 2024. doi:10.1007/s12325-024-02862-5

BibTeX
@article{Kim2024,
  author = {Kim, Hae Jin and Hur, Kyu Yeon and Lee, Yong-Ho and Kim, Jin Taek and Lee, Yong-Kyu and Baek, Ki-Hyun and Choi, Euy Jin and Hwang, Won Min and Bang, Ki Tae and Lim, Jung Soo and Chung, Yun Jae and Jo, Sung Rae and Oh, Joon Seok and Lee, Soon Hee and Ko, Seung-Hyun and Choi, Sung Hee},
  title = {Effect of Pravastatin on Kidney Function in Patients with Dyslipidemia and Type 2 Diabetes Mellitus: A Multicenter Prospective Observational Study},
  journal = {Advances in Therapy},
  year = {2024},
  doi = {10.1007/s12325-024-02862-5}
}
Kostenlos starten →